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Hereditary non-polyposis colorectal cancer is an autosomal dominant condition due to germline mutations in DNA-mismatch-
repair genes, in particular MLH1, MSH2 and MSH6. Here we describe the application of a novel technique for the detection of
genomic deletions in MLH1 and MSH2. This method, called multiplex ligation-dependent probe ampliﬁcation, is a quantitative
multiplex PCR approach to determine the relative copy number of each MLH1 and MSH2 exon. Mutation screening of genes
was performed in 126 colorectal cancer families selected on the basis of clinical criteria and in addition, for a subset of families,
the presence of microsatellite instability (MSI-high) in tumours. Thirty-eight germline mutations were detected in 37 (29.4%) of
these kindreds, 31 of which have a predicted pathogenic effect. Among families with MSI-high tumours 65.7% harboured
germline gene defects. Genomic deletions accounted for 54.8% of the pathogenic mutations. A complete deletion of the
MLH1 gene was detected in two families. The multiplex ligation-dependent probe ampliﬁcation approach is a rapid method
for the detection of genomic deletions in MLH1 and MSH2. In addition, it reveals alterations that might escape detection using
conventional diagnostic techniques. Multiplex ligation-dependent probe ampliﬁcation might be considered as an early step in
the molecular diagnosis of hereditary non-polyposis colorectal cancer.
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Hereditary non-polyposis colorectal cancer (HNPCC) is an auto-
somal dominant predisposition for early-onset colorectal cancer,
endometrial cancer and other malignant tumours. Many HNPCC
families fulﬁl the ‘Amsterdam criteria’ which require three colo-
rectal cancer patients, vertical transmission and young age at diag-
nosis (Vasen et al, 1991). In about 50% of families that meet
these criteria, germline mutations in one of the DNA-mismatch-
repair (MMR) genes MSH2 or MLH1 are detected (Wijnen et
al, 1997, 1998a). Virtually all colorectal tumours from MSH2 or
MLH1 mutation carriers show microsatellite instability (MSI),
which reﬂects the defect in DNA-mismatch-repair, and absence
of expression of the MMR gene product involved. MSI is an
important but not a speciﬁc marker of a germline MMR gene
defect: the instability can also be due to acquired hypermethyla-
tion of MLH1 (Raedle et al, 2001). A minority of HNPCC
families has a MSH6 defect or, exceptionally, a mutation in one
of the other MMR genes (Liu et al, 2001). Tumours due to
MSH6 mutations may or may not show MSI (Berends et al,
2002). Germline mutations in MMR genes can lead to a variety
of clinical presentations, including sporadic early-onset colorectal
cancer and familial endometrial cancer (Farrington et al, 1998;
Wijnen et al, 1999). Therefore, additional clinical criteria were
developed which may indicate an MMR gene defect, in particular
the Bethesda and Amsterdam II criteria (Rodriguez-Bigas et al,
1997; Vasen et al, 1999). Identiﬁcation of a germline defect in
colorectal cancer patients is crucial to establish the etiology of
the disease and to direct clinical decision making for patients
and family members.
At present, mutation detection of DNA-mismatch-repair genes
is often performed by DGGE (Denaturing Gradient Gel Electro-
phoresis), DHPLC (Denaturing High Performance Liquid
Chromatography), SSCA (Single Strand Conformation Analysis)
and direct DNA sequencing. With these methods single base substi-
tutions and small deletions and insertions can be detected.
However, genomic deletions, i.e. deletions of one or more entire
exons as well as duplications of exons will not be identiﬁed by
these techniques. Detection of this class of mutations is important
since they are an important cause of hereditary non-polyposis
colorectal cancer (Wijnen et al, 1998b).
Conventionally, the main technique used for the detection of
genomic deletions in MMR genes is Southern blotting (Wijnen et
al, 1998b). However, Southern blot analysis has several drawbacks:
the method is laborious and time-consuming and requires a rela-
tively large amount of high-quality DNA. Therefore, alternative
methods were developed based on (semi-) quantitative PCR (Char-
bonnier et al, 2000, 2002; Wang et al, 2002).
Here we describe the value of a new technique, called Multiplex
Ligation-dependent Probe Ampliﬁcation (MLPA), for determina-
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tion of this method for the analysis of genomic deletions in MSH2
and MLH1.
MATERIALS AND METHODS
We studied a cohort of colorectal cancer families investigated at the
Cancer Family Clinics of the VU University Medical Center and
the Netherlands Cancer Institute, Amsterdam, the Netherlands.
The aim of this study was to assess the value of the MLPA test
for the detection of genomic MSH2- or MLH1-deletions.
In 126 colorectal cancer families germline mutation analysis of
MSH2, MLH1 and/or MSH6 was performed. MSH1 and MLH2
were analysed in 103 kindreds. MSH6 was analysed in most
families negative for MSH2 and MLH1. In the other 23 families,
all with MSI-stable or MSI-low tumours, only MSH6 was exam-
ined.
The pedigree data either fulﬁlled the Amsterdam criteria I or II
for HNPCC or less stringent criteria, usually one or several of the
Bethesda criteria (‘suspected HNPCC’). Germline mutation screen-
ing of MMR genes was performed using DGGE or SSCA in
combination with DHPLC for MLH1 and MSH2 and DGGE for
MSH6. Investigation of MSI in tumours was performed according
to standard procedures (Boland et al, 1998). Southern blotting of
MSH2 and MLH1 was performed in one institution (VUMC) for
families with MSI-high tumours and a previous negative screening
for MMR gene defects. DNA samples from all 126 families were
subjected to MLPA analysis. Informed consent was obtained from
all patients who underwent DNA-based diagnosis.
In MLPA, illustrated in Figure 1A, probes are used that consist
of two oligonucleotides, both having a sequence complementary to
a part of a target sequence at one site and a universal primer
annealing sequence at the other site. Both hemi-probes can hybri-
dize directly adjacent to each other to a target genomic sequence. If
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Figure 1 (A) Multiplex Ligation-dependent Probe Ampliﬁcation (MLPA). Denatured genomic DNA (50–500 ng) is hybridised with a mixture of 42
probes. Each MLPA probe consists of two oligonucleotides. The two parts of each probe hybridise to adjacent target sequences and are ligated by a thermo-
stable ligase. All probe ligation products are ampliﬁed simultaneously by PCR using a single primer pair. The ampliﬁcation product of each probe has a unique
length (130–472 bp). Ampliﬁcation products are separated by capillary electrophoresis (ABI model 310 or ABI 3700). Relative amounts of probe ampliﬁca-
tion products reﬂect the relative copy number of target sequences. (B) Deletion of the entire MLH1 gene detected by MLPA. Normalised MLPA peak
pattern from the index patient of family C149 (red) and from control DNA (blue) plotted in one ﬁgure for easy comparison. MLH1 peaks are labelled
with their exon numbers. Unlabelled peaks represent MSH2 exons and control genes.
Genomic deletions of MSH2 and MLH1
JJP Gille et al
893
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(8), 892–897hybridized, the hemi-probes can be ligated and subsequently be
ampliﬁed by PCR. Non-hybridized hemi-probes do not have to
be removed since they can not be ligated and consequently will
not be ampliﬁed. By using probes with ampliﬁcation products of
different lengths, multiple probes can be used in one reaction
and be separated by gel electrophoresis for quantiﬁcation (Schou-
ten et al, 2002).
The MLPA test for MSH2 and MLH1 was obtained from MRC-
Holland, Amsterdam, the Netherlands. The probe mix contains 16
exon probes for MSH2, 19 exon probes for MLH1, and seven
control probes speciﬁc for DNA sequences outside the MSH2
and MLH1 genes. Details on probe sequences can be found on
http://www.mrc-holland.com. All incubations were performed in
a PCR machine with heated lid. Genomic DNA (50–500 ng) in
5 ml TE was denatured at 988C for 5 min. Next, 3 ml probe mix
was added and the mix was heated at 958C for 1 min. and incu-
bated at 608C for 16 h (‘overnight’). Ligation was performed
using heat-stable Ligase-65 enzyme at 548C for 15 min, followed
by ligase inactivation at 988C for 2 min. Next, 10 ml ligation mix
was added to 40 ml PCR buffer containing dNTPs, Taq polymerase
and PCR primers (one unlabelled and one FAM-labelled primer).
The reaction mixture was preheated at 958C for 1 min. followed
by 32 cycles of denaturation at 958C for 30 s, annealing at 608C
for 30 s and extension at 728C for 1 min. A ﬁnal extension was
performed at 728C for 20 min. Fragment analysis was carried out
on ABI model 310 or 3700 capillary sequencer (Applied Biosys-
tems, Forster City, CA, USA) using TAMRA-500 or ROX-500 as
size standards. A peak pattern of 42 peaks ranging in size from
130 to 472 nt is obtained.
Data analysis was performed using Genescan and Genotyper
software (Applied Biosystems). For analysing a small series of
samples, visual inspection of the peak pattern of a patient’s sample
superimposed over a peak pattern of a control is very suitable (see
Figure 1B). For analysing large series of samples, peak areas were
imported into Excel spreadsheets and peak fractions were calcu-
lated by dividing the peak area of a certain probe by the sum of
peak areas of all control probes in a certain sample. Subsequently,
this relative peak area of each probe was divided by the average
relative peak area of this probe in control samples. In normal indi-
viduals this calculation will result in a value of 1.0 representing two
copies of the target sequence in the sample.
RESULTS
The yield of germline mutation analysis according to the clinical
subgroup and the MSI status of tumours is given in Table 1. We
found germline mutations in 37 (29.4%) of the 126 colorectal
cancer families. The characteristics of these families are
summarised in Table 2. Thirty-eight germline mutations were
found, including a double mutation in one kindred (family
C222: a splice defect and an unclassiﬁed variant of MLH1), 20 in
MSH2,1 5i nMLH1 and three in MSH6. Seven (six different)
DNA alterations were of unknown clinical signiﬁcance. Thirteen
genomic deletions were identiﬁed in MSH2 and four in MLH1,
including a deletion of the entire MLH1 gene in two families
(Figure 1B). These two kindreds were found to have a common
ancestor in the eighteenth century. The clinical picture is
summarised in Figure 2. All genomic deletions detected by South-
ern blotting were conﬁrmed by MLPA.
DISCUSSION
We found a high frequency of genomic deletions in MSH2 and
MLH1 in a large cohort of colorectal cancer families. The new
MLPA technique efﬁciently detected these deletions. In general,
the yield of MMR gene mutation analysis in colorectal cancer
families depends upon: (1) the selection of families based on
clinical criteria, (2) the MSI status of tumours and/or immuno-
histochemical expression of MMR gene products, (3) the
methods used for germline mutation analysis and (4) the inter-
pretation of mutations as pathogenic vs non-pathogenic.
The families we studied include a wide range of clinical
conditions with varying indications of HNPCC. They were clas-
siﬁed into two main groups: those that fulﬁl the Amsterdam
criteria (I or II) and other ‘suspected’ families. Families from
the latter group generally satisﬁed one or more of the Bethesda
criteria. It should be noted that the description of a given family
according to the Amsterdam or Bethesda criteria does not always
give the most complete clinical information. For example, Muir–
Torre syndrome skin lesions were observed in several families
from our study group and strongly indicate HNPCC; however,
they are not mentioned in the above-mentioned criteria. In addi-
tion, many families seen in the clinic have a strong but
unconﬁrmed family history of colorectal cancer whereas the
Amsterdam and Bethesda criteria require histologically conﬁrmed
diagnoses.
In families that meet the stringent Amsterdam criteria, patho-
genic MSH2 or MLH1 mutations have been detected in about
50% of kindreds (Wijnen et al, 1997). The same yield of about
50% is found for families with less clinical indications of HNPCC
but which, in addition, have MSI-high tumours (Terdiman et al,
2001; Raedle et al, 2001). Among families that only fulﬁl clinical
criteria, usually not as stringent as the Amsterdam criteria, muta-
tions are detected in about 30% of kindreds (Wijnen et al,
1998a; Bapat et al, 1999; Lamberti et al, 1999; Syngal et al, 2000;
Wahlberg et al, 2002). Depending on the speciﬁc subgroup which
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Table 1 Yield of germline DNA-mismatch-repair gene mutation analysis in 126 colorectal cancer families
Number of germline mutations
for each gene
Description of the pedigree
Number
of families MSH2 MLH1 MSH6
Total number
of families with
germline mutations
% of families with
mutations and 95% conﬁdence
interval (binomial exact)
III
a 18 3 3 0 6 33.3 (13.3–59.0)
III & MSI-S or MSI-L 64 2 1 1 4 6.3 (1.7–15.2)
III & MSI-H 22 5 7
b 11 2
b 54.5 (32.2–75.6)
I/II
a 4 3 1 0 4 100 (39.7–100)
I/II & MSI-S or MSI-L 5 0 0 0 0 0 (0–52.2)
I/II & MSI-H 13 7 3 1 11 84.6 (54.6–98.1)
All MSI-S or MSI-L families 69 2 1 1 4 5.8 (1.6–14.1)
All MSI-H families 35 12 10 2 23
b 65.7 (47.8–80.9)
ALL FAMILIES 126 20 15 3 37
b 29.4 (21.6–38.1)
I/II=Amsterdam criteria I/II; III=suspected HNPCC; MSI=microsatellite instability. S=stable; L=low; H=high (two families had both MSI-H and MSI-S or MSI-L tumours;
aMSI not
tested or MSI could not be assessed;
bOne family had two MLH1 mutations (family C222: splice defect & unclassiﬁed variant)
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British Journal of Cancer (2002) 87(8), 892–897 ã 2002 Cancer Research UKis tested, the frequency of mutations may be lower than 10% or
higher than 90%.
Our mutation yield was 5.8% for families with MSI-S or MSI-L
tumours and 65.7% for families with MSI-H tumours (Table 1).
Our data support the notion that screening for MSI in tumours
is an efﬁcient prescreening tool for mutation analysis.
Since we included a technique for the detection of genomic
deletions which revealed a high frequency of this class of muta-
tions, one might argue that a frequency of non-deletion
mutations of 20 out of 126 kindreds (15.9%) is lower than
one would expect. Probably there are two main reasons for
the low percentage of non-deletion mutations. First, we
performed mutation analysis in a relatively large group of
families which did not meet the Amsterdam criteria (I or II)
and, in addition, had MSI-stable or MSI-low tumours. In 64
of these families we found only four (6.3%) germline muta-
tions. These mutations include three unclassiﬁed variants in
MSH2 and MSH1 and one pathogenic MSH6 mutation. It has
been observed before that deleterious MSH6 mutations may
be accompanied by MSI-low tumours (Berends et al, 2002).
Second, in several families all affected individuals had died
and, consequently, only at-risk family members were available
for testing.
The methods we used for the analysis of point mutations were
DGGE or SSCA in combination with DHPLC for MSH2 and
MLH1 and DGGE for MSH6. These techniques are highly sensitive
and speciﬁc for the detection of mutations in the coding regions of
these genes (Wahlberg et al, 1999). Mutations in the promoter
regions of MSH2 and MLH1 will not be detected by these methods;
however, they seem to play a limited role (Shin et al, 2002). We
found six different mutations in MSH2 and MLH1 categorised as
unclassiﬁed variants; their clinical signiﬁcance is uncertain.
However, the Thr117Met variant in MLH1 most probably has a
pathogenic effect as demonstrated in a recently developed in vitro
assay (Trojan et al, 2002).
In our cohort of colorectal cancer families more than 50% of the
pathogenic mutations were genomic deletions. Evidently, genomic
deletions in MLH1 and MSH2 are an important cause of HNPCC
in Dutch colorectal cancer families. It has been reported previously
that MSH2 genomic deletions are frequent in this group. Haplo-
type analysis of the kindreds sharing the same deletions failed to
show evidence of a founder effect (Wijnen et al, 1998b). Only
two MLH1 deletions had been reported at that time, one of which
was a founder mutation that accounted for a large proportion of
HNPCC kindreds in the Finnish population (Nystro ¨m-Lahti et
al, 1995; Mauillon et al, 1996). In a recent study of German
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Table 2 DNA-mismatch-repair-gene germline mutations in 37 colorectal cancer families
Germline DNA-mismatch-repair gene mutation #
Family identiﬁcation Description of pedigree MSI studies** MSH2 MLH1 MSH6 Remarks
C001 I – Del exon 7
C005 II H Del exons 1–6
C007 I – 1917 G4A (a),(b)
C010 I – 1139delT
C011 I – 1595insG
C021 I H Del exon 2
C030 II H & S 4001 G4A (a),(c)
C032 I H Thr117Met UV,(d)
C063 III H Del exon 3
C073 III – Del exon 6
C080 I H Gln429stop
C135 III H Del exons 1–6
C149 III H Del exons 1–19 (e)
C157 III S Lys93del UV
C161 III – Del exons 1–7
C162 III – Del exon 12
C198 III H Asn38His UV
C222 III H IVS9+3A4T & Lys618Ala (a) & UV
C261 III L 3182delT
C263 III H 1270insA (e)
C278 III H Met35Asn UV
C288 III S Lys618Ala UV
C293 III – Del exons 1–19
C321 III H 652insT
C361 III – 2001insA
C369 III – IVS3+1G4A (e)
F063 I H Del exons 1–6
F066 I H Del exon 7
F075 II H Del exon 12
F221 I H Del exons 1–7
F239 II H Del exon 3
F242 III H Del exons 1–3
F423 I H 677G4A (a)
F456 III H Del exon 3
F538 III H IVS13-2A4G
F692 II H 18del17
F776 III S Met813Val UV
I/II=Amsterdam criteria I/II; III=suspected HNPCC; **: hMSI=microsatellite instability; S=stable; L=low; H=high; –: MSI-studies not performed; #: mutations detected by MLPA
indicated in bold type; (a) splice defect; (b) kindred also described by Wijnen et al, 1997 (NL-4); (c) kindred also described by Menko et al, 1994; Wijnen et al, 1999 (NA-22); (d)
pathogenicity assessed by in vitro test (Trojan et al, 2002); (e) clinical picture includes Muir–Torre syndrome; UV=unclassiﬁed variant
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(Wang et al, 2002). Recently, deletion mutations have also been
demonstrated in series of European and US colorectal cancer
kindreds, but at a much lower frequency than in our study group
(Wijnen JTh, personal communication). We found 17 genomic
deletions, 13 in MSH2 and four in MLH1. These included at least
nine different subtypes, which might imply that the high frequency
of deletions in our study group is not caused by a strong founder
effect. However, ﬁve deletions occurred in multiple kindreds and a
common ancestor was demonstrated for the MLH1 deletion.
Future studies will clarify the frequency and background of geno-
mic deletions in MSH2 and MLH1 in different populations.
A deletion of the entire MLH1 gene has not been described
before. In the two kindreds involved, the clinical expression
included Muir–Torre syndrome and very-early-onset colonic
cancer. A deletion of the complete MSH2 gene in an HNPCC
family was recently described by Wang et al (2002).
In summary, the MLPA technique is a fast and efﬁcient test for
the detection of genomic deletions in MMR genes. In contrast with
the PCR- based techniques described by Charbonnier et al (2002)
and Wang et al (2002) deletion screening of MSH2 and MLH1
by MLPA can be performed in a single procedure. Compared with
the MAPH method developed recently (Armour et al, 2000) MLPA
is easier to perform. The technique allows the detection of dele-
tions that might escape detection using Southern blot analysis. In
particular, interpretation of Southern blotting results may be difﬁ-
cult in case of the deletion of an entire gene.
Clearly, screening for genomic deletions in MSH2 and MLH1 is
an essential procedure for the molecular diagnosis of HNPCC. Due
to the advantages of the MLPA technique, screening for these dele-
tions might be considered as an early step in MMR gene mutation
analysis.
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